(Q45917918)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Dong Jin Suh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Kang Mo Kim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Young-Suk Lim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Han Chu Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Young-Hwa Chung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Yung Sang Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

1064-1071

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19637288%20AND%20SRC:MED&resulttype=core&format=json

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

3 February 2020

cites work

1 reference

Antiviral drug resistance: clinical consequences and molecular aspects

21 January 2018

1 reference

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

Molecular virology and the development of resistant mutants: implications for therapy

21 January 2018

1 reference

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

21 January 2018

1 reference

21 January 2018

1 reference

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

21 January 2018

1 reference

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

21 January 2018

1 reference

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients

21 January 2018

1 reference

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

21 January 2018

1 reference

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 January 2018

1 reference

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

21 January 2018

1 reference

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

21 January 2018

1 reference

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

Cellular and virological mechanisms of HBV drug resistance

21 January 2018

1 reference

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

21 January 2018

1 reference

[Management of Chronic Hepatitis B]

21 January 2018

1 reference